4.0
Oct 20, 2012
Anonymous employee
Current employee
Recommend
CEO approval
Business Outlook
Pros
The leading CNS specialty firm, and only company with a late stage pipeline in the big disease areas depression, psychosis and Alzheimer's
Cons
Development risk is still high, and recent patent expires make cost optimisation important, commercial plans and ideas will get closely scrutinised before being committed to